MyFinsight
Home
Blog
About
DiaMedica Therapeutics Inc. (DMAC)
DiaMedica Therapeutics Inc. (DMAC)
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Change in Cash
$261K
Free Cash flow
-$8,117K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
Maturities and sales of marketab...
Accrued liabilities
Share-based compensation
Others
Negative Cash Flow Breakdown
Purchase of marketable securitie...
Accounts payable
Amortization of discounts on mar...
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Total operating expenses, excluding share-based compensation
-
9,660
8,021
8,017
Total share-based compensation
-
822
1,192
1,016
Total operating expenses, excluding share-based compensation
19,040
-
-
-
Operating loss
-
-10,482
-9,213
-9,033
Interest income
-
470
472
440
Other expense, net
-
23
10
-
Total share-based compensation
1,940
-
-
-
Operating loss
-20,980
-
-
-
Interest income
855
-
-
-
Other income (expense), net
-
-
-
-21
Other income, net
-42
-
-
-
Income tax expense
7
7
10
18
Net loss
-10,139
-10,042
-8,740
-8,620
Share-based compensation
1,118
822
1,192
1,016
Amortization of discounts on marketable securities
169
190
252
249
Non-cash lease expense
22
22
21
21
Depreciation
12
11
11
18
Amounts receivable
-57
43
-2
99
Prepaid expenses and other assets
-164
250
36
-235
Deposits
0
0
-200
0
Accounts payable
-481
1,818
-445
659
Accrued liabilities
1,302
-1,230
282
469
Net cash used in operating activities
-8,114
-9,082
-7,765
-6,550
Purchase of marketable securities
4,754
18,896
8,054
34,854
Maturities and sales of marketable securities
13,000
16,790
16,055
9,104
Purchase of property and equipment
3
8
6
16
Net cash provided by (used in) investing activities
8,243
-2,114
7,995
-25,766
Proceeds from the sale of common shares, net of offering costs
-
-
11,755
31,527
Proceed from the exercise of common stock options
135
420
282
465
Deferred financing costs, net
-
-
-56
456
Principal payments on finance lease obligations
3
3
2
3
Net cash provided by financing activities
132
417
12,091
31,533
Net increase (decrease) in cash and cash equivalents
261
-10,779
12,321
-783
Cash and cash equivalents at beginning of period
4,868
15,647
3,326
3,025
Cash and cash equivalents at end of period
5,129
4,868
15,647
3,326
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Maturities and sales of
marketable securities
$13,000K
(-59.33%↓ Y/Y)
Proceed from the
exercise of common stock...
$135K
(-47.47%↓ Y/Y)
Net cash provided by
(used in) investing...
$8,243K
(-47.09%↓ Y/Y)
Net cash provided by
financing activities
$132K
(-47.62%↓ Y/Y)
Canceled cashflow
$4,757K
Canceled cashflow
$3K
Net increase
(decrease) in cash and cash...
$261K
(-75.92%↓ Y/Y)
Canceled cashflow
$8,114K
Purchase of marketable
securities
$4,754K
(-70.96%↓ Y/Y)
Purchase of property and
equipment
$3K
(-83.33%↓ Y/Y)
Accrued liabilities
$1,302K
(179.25%↑ Y/Y)
Share-based compensation
$1,118K
(-31.75%↓ Y/Y)
Prepaid expenses and
other assets
-$164K
(-136.20%↓ Y/Y)
Amounts receivable
-$57K
(24.00%↑ Y/Y)
Non-cash lease expense
$22K
(-45.00%↓ Y/Y)
Depreciation
$12K
(-14.29%↓ Y/Y)
Principal payments on
finance lease...
$3K
(-40.00%↓ Y/Y)
Net cash used in
operating activities
-$8,114K
(44.98%↑ Y/Y)
Canceled cashflow
$2,675K
something is missing
$10,035K
Interest income
$855K
(12.95%↑ Y/Y)
Net loss
-$10,139K
(34.19%↑ Y/Y)
Canceled cashflow
$10,890K
Accounts payable
-$481K
(-249.84%↓ Y/Y)
Amortization of discounts on
marketable securities
$169K
(-61.68%↓ Y/Y)
Operating loss
-$20,980K
(-29.90%↓ Y/Y)
Other income, net
-$42K
Income tax expense
$7K
(-41.67%↓ Y/Y)
Total operating
expenses, excluding...
$19,040K
(31.19%↑ Y/Y)
Total share-based
compensation
$1,940K
(18.44%↑ Y/Y)
Buy us a coffee